Privacy-Preserving Healthcare AI Under EU AI Act: ISO 42001 Compliance Guide for Taiwan

Winners Consulting Services Co., Ltd. believes a 2025 study, already cited 12 times, clearly reveals a critical vulnerability: for medical AI systems classified as high-risk under the EU AI Act, data encryption alone is no longer sufficient to counter new threats like federated learning inference attacks and membership inference. Taiwanese companies in digital health and precision medicine must upgrade their privacy frameworks from mere "compliance documentation" to "verifiable technical controls" within the next 3 to 5 years, or face dual barriers to EU market access and ISO 42001 certification.

About the Authors and This Research

This paper was co-authored by researchers Konstantinos Kalodanis, G. Feretzakis, and Athanasios Anastasiou, and published in the MDPI journal Electronics (DOI: 10.3390/electronics14071385). The authors are established experts in medical information system security, Privacy-Preserving Machine Learning (PPML), and clinical AI compliance. Their research, which bridges technical implementation and regulatory interpretation, has earned them significant recognition within the European medical AI academic community.

Since its publication in 2025, the paper has garnered 12 citations, including one high-impact citation, highlighting its academic standing at the intersection of AI governance and medical privacy. Notably, this is not merely a technical paper. It uses the EU AI Act's high-risk classification framework as its foundation to systematically integrate privacy attack taxonomies, federated learning architectures, secure computation protocols, and continuous monitoring mechanisms. This provides a practical blueprint for both designers and compliance officers of medical AI systems.

Medical AI Privacy Threats Are More Complex Than Companies Realize: Core Insights from the Paper

The paper's most significant contribution is its rejection of the simplistic "encryption equals privacy" mindset. Instead, it systematically categorizes the types of attacks facing ML-based medical systems and proposes an adaptive technical architecture to counter these threats.

Core Finding 1: Privacy Attacks on Medical AI Have Diverged into "Data-Centric" and "Model-Centric" Categories

The researchers classify privacy attacks on ML medical systems into two dimensions: Data-Centric Attacks, including training data poisoning and data reconstruction attacks; and Model-Centric Attacks, which encompass Membership Inference Attacks, Model Inversion Attacks, and Attribute Inference Attacks. This taxonomy holds direct practical value for Taiwanese medical institutions and health-tech companies. Traditional cybersecurity risk assessments often focus solely on data breaches, overlooking the possibility of the model itself becoming an attack vector. Under a Federated Learning architecture, even if raw patient data never leaves the local device, an attacker could still potentially reconstruct personal health information by analyzing model gradients.

Core Finding 2: An Adaptive Encryption Strength Algorithm—Aligning Compliance Costs with Risk Levels

The most innovative element of the proposed architecture is an "independent adaptive algorithm" that automatically adjusts cryptographic protection strength based on three contextual factors: risk severity, computational resource capacity, and the current regulatory environment. This design addresses a long-standing paradox in AI privacy protection: the strongest methods (like Homomorphic Encryption) often incur prohibitive computational costs, making clinical deployment impractical, while lighter mechanisms may fail to meet the stringent requirements of GDPR and the EU AI Act. An adaptive mechanism that dynamically adjusts protection levels based on risk is a pragmatic solution that balances compliance and operational efficiency. Furthermore, the paper emphasizes that the Ongoing Monitoring Mechanism must align with EU AI Act specifications and GDPR standards, a requirement that closely mirrors ISO 42001 Clause 9 on performance evaluation for AI management systems.

Implications for AI Governance in Taiwan: Three Structural Challenges to Address

The warnings from this paper extend far beyond the healthcare industry for Taiwanese companies. Any AI application that processes personal health data, biometrics, or other sensitive information should incorporate the study's findings into its risk assessment framework.

First, the scope of the EU AI Act's high-risk classification is broader than most Taiwanese companies anticipate. According to Article 3 and Annex III of the Act, medical AI systems (including those for diagnostic support, treatment planning, and patient monitoring) are classified as High-Risk AI Systems, requiring rigorous conformity assessments before market entry. Taiwanese medical device manufacturers, health-tech startups, and telehealth platforms planning to enter the EU market must integrate Privacy-Preserving ML into their architecture from the design phase, not as an afterthought. Taiwan's AI Basic Act, in Article 7, also emphasizes risk-based management, echoing the spirit of the EU AI Act and signaling a likely convergence of local regulations toward similar high-risk standards.

Second, ISO 42001 certification cannot remain at the level of "paper compliance." ISO 42001 is one of the world's most systematic frameworks for AI privacy governance, and its Clause 6.1.2 requires organizations to establish processes for identifying and assessing AI-specific risks. The membership inference and model inversion attacks highlighted in this paper are prime examples of the "AI-specific threats" that must be addressed in an ISO 42001 risk assessment. If a company merely lists these risks in documentation without implementing corresponding technical controls (such as Differential Privacy or Secure Multi-Party Computation), it will face significant non-conformities during a third-party audit.

Third, continuous monitoring will be the core compliance battleground after 2026. Recent AI governance guidance from NIST and updates from the EDPB both indicate a regulatory shift from pre-market review to ongoing monitoring. The continuous monitoring framework proposed in the paper—which tracks model behavior anomalies, gradient leakage indicators, and inference drift—corresponds directly to the performance monitoring requirements of ISO 42001 Clause 9 and the post-market monitoring obligations for high-risk AI systems under Article 72 of the EU AI Act. The monitoring mechanisms Taiwanese companies establish today will determine their ability to operate in the EU market 3 to 5 years from now.

How Winners Consulting Services Helps Taiwanese Companies Establish Medical AI Privacy Governance

Winners Consulting Services Co., Ltd. helps Taiwanese companies establish AI management systems that comply with ISO 42001 and the EU AI Act, conduct AI risk assessments, and ensure their AI applications align with Taiwan's AI Basic Act. To address the medical AI privacy governance challenges highlighted in this paper, we recommend Taiwanese companies take the following concrete actions:

1. Conduct an AI Privacy Attack Scenario Assessment: Systematically review existing medical AI or health data applications using the paper's attack taxonomy. Ensure that ML-specific threats like membership inference and model inversion attacks are included in the Risk Register, in line with the AI risk identification requirements of ISO 42001 Clause 6.1.2, and establish a clear mapping between threat scenarios and technical controls.
2. Establish Technical Privacy Protection Verification Mechanisms: Evaluate whether existing AI systems have implemented Privacy-Preserving Machine Learning techniques such as differential privacy, federated learning, or secure multi-party computation. Establish a quantifiable Privacy Budget management process. This is not only a GDPR requirement but also a specific mandate for data governance in high-risk AI systems under Article 10 of the EU AI Act, and a key focus for auditors reviewing technical controls for ISO 42001.
3. Design a Continuous Monitoring Dashboard Compliant with EU AI Act Article 72: Implement a Post-Market Monitoring system to track model performance degradation, bias drift, and privacy leakage risk indicators. Ensure that monitoring records provide full traceability for audits. Winners Consulting Services can guide companies through the entire implementation process, from initial diagnosis to the establishment of a monitoring framework, typically within 7 to 12 months.

Frequently Asked Questions

What is a Membership Inference Attack in medical AI systems, and how can companies defend against it?

A Membership Inference Attack allows an attacker to query a trained AI model to determine if a specific individual's data, such as a patient's health record, was part of the model's training set, thereby inferring sensitive information. This attack remains a threat even in federated learning architectures, as model gradients can leak features of the training data. To defend against it, companies should deploy Differential Privacy mechanisms with a defined privacy budget (ε-value) to add statistical noise, formally list membership inference as a standard threat scenario in their AI-specific risk assessment under ISO 42001 Clause 6.1.2, and establish regular adversarial testing to validate defenses. The accuracy and robustness requirements for high-risk AI systems under Article 15 of the EU AI Act also imply an obligation to protect against such attacks.

How can Taiwanese medical device or health-tech companies determine if their AI product falls under the EU AI Act's high-risk category?

An AI product is likely classified as high-risk under the EU AI Act if it is intended for medical diagnostic support, treatment decisions, patient risk assessment, or managing life-sustaining equipment, as specified in Annex III. The determination process involves three steps: first, confirm the product meets the legal definition of an "AI system" under Article 3; second, check if its function falls into the high-risk use cases listed in Annex III; third, assess if it is also regulated under the EU's Medical Device Regulation (MDR) or In Vitro Diagnostic Regulation (IVDR), which solidifies its high-risk status. As Taiwan's AI Basic Act also promotes risk-based classification, companies should establish a dual-track compliance assessment for both domestic and EU regulations, using ISO 42001 certification as supporting evidence of conformity.

What are the core requirements of ISO 42001 certification for medical AI companies, and how long does implementation take?

ISO 42001 certification requires establishing an AI Management System (AIMS) with core components including organizational context analysis (Clause 4), AI-specific risk and opportunity assessment (Clause 6.1.2), AI system lifecycle management (Clause 8), performance monitoring (Clause 9), and continual improvement (Clause 10). For medical AI companies, building robust threat scenarios for Clause 6.1.2, including ML-specific attacks, and establishing continuous monitoring mechanisms for Clause 9 are particularly critical. Based on our consulting experience, implementation from initial diagnosis to third-party certification typically takes 7-12 months for general companies. For the medical industry, this timeline often extends to 10-14 months due to the need to align with MDR/IVDR compliance. We recommend starting with an AI application inventory and gap analysis to accurately scope the implementation project.

How can the actual costs and benefits of implementing differential privacy or federated learning in medical AI be assessed?

The costs and benefits of implementing privacy-enhancing technologies (PETs) depend heavily on the organization's scale and the AI system's complexity. For a mid-sized medical institution, the initial setup cost for a federated learning architecture typically accounts for 15-25% of the total AI project budget, while software-level implementation of differential privacy is lower, around 5-10%. On the benefits side, implementing PETs can reduce the risk of GDPR non-compliance fines by an estimated 60-70%; these fines can reach up to 4% of global annual turnover or €20 million. Furthermore, ISO 42001 certification provides a significant competitive advantage in EU public procurement, with some healthcare authorities making it a prerequisite. Companies should evaluate the 3-to-5-year return on investment (ROI) rather than focusing solely on initial costs.

Why choose Winners Consulting Services for assistance with AI governance issues?

Winners Consulting Services Co., Ltd. is one of the few professional consulting firms in Taiwan with comprehensive capabilities in ISO 42001 implementation, EU AI Act compliance assessment, and medical AI privacy governance. Our team combines cross-disciplinary expertise in ISO 27001/27701 information security, PIMS privacy management, and AI governance, enabling us to help companies meet both EU AI Act and GDPR requirements while aligning with Taiwan's AI Basic Act. We provide end-to-end services, from a free initial diagnostic and gap analysis to management system design and third-party audit support. A typical implementation project is completed within 7 to 12 months, establishing a sustainable, long-term AI governance capability for your organization.